Sabitlenmiş Tweet
Psilocybin and the Next Phase of Mental Health Innovation | @flobrand and @LarsWilde (Part 2)
$CMPS $ATAI $DFTX $HELP $GHRS
youtube.com/watch?v=MwDlQ1…
YouTube
English
Psychedelic Vantage
2.8K posts
Psychedelic Vantage
@PsychedVantage
Venturing into the world of psychedelic drug development, research, investing, and more. Sharing insights and interviewing leading figures in the field.
Katılım Kasım 2021
881 Takip Edilen1.8K Takipçiler
Psychedelic Vantage retweetledi
New essay:
The Route Problem in Psychiatry
An effective antidepressant was pulled from the market because no one could figure out how to deliver it.
A well-tolerated European drug never submitted for U.S. approval because of a liver tox signal.
Mechanism is sexy; route is destiny.
open.substack.com/pub/darkmatter…
English
Psychedelic Vantage retweetledi
Setbacks in mental health recovery aren’t failure; they’re part of the process. 🧠
In this video, Dr. Matt Bernstein explains why downturns are normal, how to prepare for them, and how the right mindset can turn challenges into growth in your mental health journey.
English
@ChartGuys Huge year for $DFTX rich with potential catalysts.
English
@PsychedVantage DFTX out performance has been very impressive the last couple months
English
Update:
Added to $ATAI position today
I will provide updated neuropsychiatry drug development portfolio allocation later tonight.
As always, this is not investment advice. I share to stay transparent and spark conversation in the community.
-Jake
Psychedelic Vantage@PsychedVantage
Update: Sold out of $HELP in pre-market trading. I still hold $ATAI and $ANRO in the neuropsych portfolio. As always, this is not investment advice. I share to stay transparent and spark conversation in the community. -Jake
English
Psychedelic Vantage retweetledi
Psychedelic Vantage retweetledi
AbbVie's bretisilocin has become the first psychedelic to receive Priority Medicines (PRIME) eligibility from the European Medicines Agency
English
BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation
$ATAI
ir.ataibeckley.com/news-releases/…
English
Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults
A Randomized Clinical Trial
#google_vignette" target="_blank" rel="nofollow noopener">jamanetwork.com/journals/jamap…
“LSD was not efficacious in reducing ADHD symptoms compared with placebo; these results question the anecdotal practice and highlight the importance of placebo-controlled trials in low-dose psychedelic research.”
Stimulant medications show some of the largest effect sizes out of all psychiatric drugs in the psychiatrist’s toolbox.
Taylor Sterling@FatherMcKennaa
Your psychiatrist will never say this, but 12μg of LSD every MWF beats prescription stimulants. → dramatically cheaper → fewer, cleaner side effects → impossible to get addicted to (tolerance) → builds better habits instead of dependence on a pill
English
Psychedelic Vantage retweetledi
1 dose of psilocybin with manualized CBT increased long-term abstinence compared with nicotine patch treatment with CBT. Psilocybin abstinence rates were higher than typical treatments, suggesting promise for tobacco smoking cessation.
ja.ma/413izIp
English
Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer
$HELP
ir.helus.com/investors/news…
English
Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 2026
$CMPS
ir.compasspathways.com/News--Events-/…
English
Psychedelic Vantage retweetledi
𝐁𝐚𝐫𝐜𝐥𝐚𝐲𝐬 𝐌𝐢𝐚𝐦𝐢: @ReunionNeuro received Breakthrough Therapy Designation from FDA for its psychedelic based treatment for postpartum depression (PPD).
Full video: biotechtv.com/post/reunion-n…
English
Psychedelic Vantage retweetledi
Just published: our RCT shows psilocybin (magic mushrooms) dramatically beats nicotine patch for quitting smoking using the same psychotherapy! A single psilocybin session showed 6x greater odds of staying quit. Biologically verified. In @JAMANetworkOpen Thread 🧵 #Psychedelics #QuitSmoking
English
Psychedelic Vantage retweetledi
1/ When @LarsWilde and I flagged increasing pharma interest in psychedelics as a very encouraging sign last year, some thought it was premature. Turns out it wasn’t. A thread 🧵
$ATAI $CMPS $DFTX $GHRS
English
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day
$ATAI
ir.ataibeckley.com/news-releases/…
English
Updated neuropsychiatry drug development portfolio allocation (Individual + Roth IRA):
After selling around 18% of my original $ATAI position in the 5.70-6.70 range, I am happy to say I am back to my original share count.
Many ask me what else I invest in. It is mostly boring stuff like $VOO, $VTI, and $SCHD. Recently set up automatic recurring investments to purchase $FBTC weekly, over the next year.
As always, this is not investment advice. I share to stay transparent and spark conversation in the community.
-Jake
Psychedelic Vantage@PsychedVantage
Update: Added to $ATAI position today I will provide updated neuropsychiatry drug development portfolio allocation later tonight. As always, this is not investment advice. I share to stay transparent and spark conversation in the community. -Jake
English
Would love to see $ATAI expand into SUDs. 5-MeO-DMT has a good shot at showing efficacy in AUD and cocaine use disorder, IMO. MOUD and MAUD are underutilized in real-world clinical practice.
More options are needed for patients!
Psychedelic Alpha@Psyched_Alpha
AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal psychedelicalpha.com/news/ataibeckl…
English
Psychedelic Vantage retweetledi
AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal
psychedelicalpha.com/news/ataibeckl…
English
@DrAdamBorecky Always a pleasure reading your analysis. Very much appreciate the voice over as well (brain is mush this week from reading so much for grad school). If you had time, would love to see a piece about current evidence for Pramipexole in TRD and ALTO-207 (fixed-dose combination of Pramipexole and Ondansetron) set to enter into phase 2b/3 studies soon.
-Jake
English
@therealRYC This is a great breakdown, Robert. We were thinking about the same thing this week. Im a little late to the party, but I tried to ask the same questions you did for the $CMPS phase 3 readouts.
open.substack.com/pub/darkmatter…
English
🚨Cybin (now Helus) just dropped phase 2 data from its deuterated DMT analog
The headline: resounding response in “treatment resistant” anxiety.
But is that fact? Or mostly fiction.
Here’s how to read between the lines in psychiatric drug trials 📝
Robert Y. Chen@therealRYC
English
Psychedelic Vantage retweetledi
Bloomberg: AtaiBeckley Inc. is exploring options for its flagship psychedelic drug candidate, BPL-003, including a potential sale or partnership.
Seeking $2bn+
bloomberg.com/news/articles/…
English